Irrimax Corporation is focused on reducing infections, healthcare costs and improving patient outcomes.

Innovation Technologies, Inc., parent company to Irrimax Corporation, holds the rights to US and worldwide patents that provide broad protection for the use of low-concentration CHG (at less than 1%) technology. The company’s flagship product, Irrisept Antimicrobial Wound Lavage, is a single-use, manual, self-contained irrigation device comprised of 0.05% Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water for Irrigation, United States Pharmacopeia (USP).

Irrimax has attracted experts in the fields of product development, clinical research, manufacturing and distribution. Our management team is committed to leading the organization according to high standards of integrity and accountability.